File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.athoracsur.2006.05.116
- Scopus: eid_2-s2.0-33750063968
- PMID: 17062221
- WOS: WOS:000241497600011
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Chylothorax in Children After Congenital Heart Surgery
Title | Chylothorax in Children After Congenital Heart Surgery |
---|---|
Authors | |
Issue Date | 2006 |
Publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/athoracsur |
Citation | Annals Of Thoracic Surgery, 2006, v. 82 n. 5, p. 1650-1656 How to Cite? |
Abstract | Background: A definitive management strategy for postoperative chylothorax remains elusive. We reviewed our experience in the management of chylothorax in children after congenital heart surgery. Methods: The case records of 51 patients, with a median age of 11 months (range, 4 days to 19.6 years), diagnosed to have postoperative chylothorax between 1981 and 2004 were reviewed. The responses of patients to nutritional modifications, octreotide therapy, and surgical interventions were noted. Results: The prevalence of postoperative chylothorax, which developed at a median of 9 days after operation (range, 0 to 24 days), was 0.85% (51 of 5,995). Four patients died, and among the 47 survivors the median duration and total volume of chylous drainage was 15 days (range, 1 to 89 days) and 156 mL/kg (range, 3 to 6,476), respectively. The duration of chyle output was significantly longer after the Fontan-type procedures (p = 0.0006). Twenty-one patients were diagnosed between 1981 and 1999 and managed by nutritional modifications, 2 of whom required further surgical interventions. Of the 30 patients diagnosed between 2000 and 2004, 12 responded to nutritional modifications alone while 18 were started on octreotide therapy at a median of 19.5 days (range, 7 to 35 days) after the onset of chylothorax. Fifteen of the 18 (83%) patients responded to octreotide therapy at 15.3 ± 5.5 days after starting octreotide, while 3 required further surgical interventions. None developed side effects from octreotide therapy. Conclusions: Octreotide has been incorporated into the management algorithm of postoperative chylothorax and appears to be a useful adjunctive therapy. © 2006 The Society of Thoracic Surgeons. |
Persistent Identifier | http://hdl.handle.net/10722/170379 |
ISSN | 2023 Impact Factor: 3.6 2023 SCImago Journal Rankings: 1.203 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Chan, Sy | en_US |
dc.contributor.author | Lau, W | en_US |
dc.contributor.author | Wong, WHS | en_US |
dc.contributor.author | Cheng, Lc | en_US |
dc.contributor.author | Chau, AKT | en_US |
dc.contributor.author | Cheung, Yf | en_US |
dc.date.accessioned | 2012-10-30T06:07:54Z | - |
dc.date.available | 2012-10-30T06:07:54Z | - |
dc.date.issued | 2006 | en_US |
dc.identifier.citation | Annals Of Thoracic Surgery, 2006, v. 82 n. 5, p. 1650-1656 | en_US |
dc.identifier.issn | 0003-4975 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/170379 | - |
dc.description.abstract | Background: A definitive management strategy for postoperative chylothorax remains elusive. We reviewed our experience in the management of chylothorax in children after congenital heart surgery. Methods: The case records of 51 patients, with a median age of 11 months (range, 4 days to 19.6 years), diagnosed to have postoperative chylothorax between 1981 and 2004 were reviewed. The responses of patients to nutritional modifications, octreotide therapy, and surgical interventions were noted. Results: The prevalence of postoperative chylothorax, which developed at a median of 9 days after operation (range, 0 to 24 days), was 0.85% (51 of 5,995). Four patients died, and among the 47 survivors the median duration and total volume of chylous drainage was 15 days (range, 1 to 89 days) and 156 mL/kg (range, 3 to 6,476), respectively. The duration of chyle output was significantly longer after the Fontan-type procedures (p = 0.0006). Twenty-one patients were diagnosed between 1981 and 1999 and managed by nutritional modifications, 2 of whom required further surgical interventions. Of the 30 patients diagnosed between 2000 and 2004, 12 responded to nutritional modifications alone while 18 were started on octreotide therapy at a median of 19.5 days (range, 7 to 35 days) after the onset of chylothorax. Fifteen of the 18 (83%) patients responded to octreotide therapy at 15.3 ± 5.5 days after starting octreotide, while 3 required further surgical interventions. None developed side effects from octreotide therapy. Conclusions: Octreotide has been incorporated into the management algorithm of postoperative chylothorax and appears to be a useful adjunctive therapy. © 2006 The Society of Thoracic Surgeons. | en_US |
dc.language | eng | en_US |
dc.publisher | Elsevier Inc. The Journal's web site is located at http://www.elsevier.com/locate/athoracsur | en_US |
dc.relation.ispartof | Annals of Thoracic Surgery | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Cardiac Surgical Procedures - Adverse Effects | en_US |
dc.subject.mesh | Child | en_US |
dc.subject.mesh | Child, Preschool | en_US |
dc.subject.mesh | Chylothorax - Etiology - Therapy | en_US |
dc.subject.mesh | Diet Therapy | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Gastrointestinal Agents - Therapeutic Use | en_US |
dc.subject.mesh | Heart Defects, Congenital - Surgery | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Infant | en_US |
dc.subject.mesh | Infant, Newborn | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Octreotide - Therapeutic Use | en_US |
dc.subject.mesh | Triglycerides - Therapeutic Use | en_US |
dc.title | Chylothorax in Children After Congenital Heart Surgery | en_US |
dc.type | Article | en_US |
dc.identifier.email | Cheung, Yf:xfcheung@hku.hk | en_US |
dc.identifier.authority | Cheung, Yf=rp00382 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.athoracsur.2006.05.116 | en_US |
dc.identifier.pmid | 17062221 | - |
dc.identifier.scopus | eid_2-s2.0-33750063968 | en_US |
dc.identifier.hkuros | 125118 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-33750063968&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 82 | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.spage | 1650 | en_US |
dc.identifier.epage | 1656 | en_US |
dc.identifier.isi | WOS:000241497600011 | - |
dc.publisher.place | United States | en_US |
dc.identifier.scopusauthorid | Chan, Sy=7404255845 | en_US |
dc.identifier.scopusauthorid | Lau, W=7402933338 | en_US |
dc.identifier.scopusauthorid | Wong, WHS=13310222200 | en_US |
dc.identifier.scopusauthorid | Cheng, Lc=9533935800 | en_US |
dc.identifier.scopusauthorid | Chau, AKT=35787094400 | en_US |
dc.identifier.scopusauthorid | Cheung, Yf=7202111067 | en_US |
dc.identifier.issnl | 0003-4975 | - |